Scarica l'app Stockscreener
7.96
5.43%
0.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.55
Aprire:
$7.64
Volume 24 ore:
220.61K
Relative Volume:
1.79
Capitalizzazione di mercato:
$271.86M
Reddito:
$21.25M
Utile/perdita netta:
$-16.05M
Rapporto P/E:
-13.05
EPS:
-0.61
Flusso di cassa netto:
$-17.14M
1 W Prestazione:
+5.57%
1M Prestazione:
+1.27%
6M Prestazione:
+0.38%
1 anno Prestazione:
+31.57%
Intervallo 1D:
$7.635
$8.00
Intervallo di 1 settimana:
$7.35
$8.00
Portata 52W:
$4.68
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Nome
Fennec Pharmaceuticals Inc
Settore
Industria
Telefono
(919) 636-4530
Indirizzo
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Confronta FENC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
7.96 | 257.86M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Iniziato | CapitalOne | Overweight |
| 2022-08-08 | Ripresa | Craig Hallum | Buy |
| 2020-06-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Iniziato | Goldman | Buy |
Fennec Pharmaceuticals Inc Borsa (FENC) Ultime notizie
(FENC) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Fennec Pharmaceuticals (TSX:FRX) Operate Today In Precision Oncology - Kalkine Media
(FRX) Equity Market Report (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals (TSE:FRX) Insider Sells C$1,799,524.00 in Stock - MarketBeat
Fennec's Pedmarqsi gets nod from U.K. regulators - MSN
Fennec Pharmaceuticals Announces Private Offering to Bolster Financial Position - MSN
(FRX) Risk-Controlled Trading Report (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment - TipRanks
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Pfizer (PFE) - The Globe and Mail
How To Trade (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Tumors - marketscreener.com
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors - marketscreener.com
Fennec Pharma announces City of Hope PEDMARK trial in metastatic testicular tumors | FENC Stock News - Stock Titan
(FRX) Trading Performance and Risk Management (FRX:CA) - news.stocktradersdaily.com
Retail Surge: Will Fennec Pharmaceuticals Inc RV41 stock hit Wall Street targetsMarket Volume Report & Real-Time Sentiment Analysis - BỘ NỘI VỤ
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus
Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400 - Investing.com
Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400 By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Director Sells 10,000 Shares - TradingView
Dir Raykov Sells 10,000 ($75.4K) Of Fennec Pharmaceuticals Inc [FENC] - TradingView
Dir Raykov Files To Sell 10,000 Of Fennec Pharmaceuticals Inc [FENC] - TradingView
What hedge fund moves indicate for Fennec Pharmaceuticals Inc. (RV41) stockQuarterly Portfolio Report & Safe Investment Capital Preservation Plans - Newser
Will Fennec Pharmaceuticals Inc. (RV41) stock hit Wall Street targetsTake Profit & Fast Entry High Yield Tips - Newser
Can Fennec Pharmaceuticals Inc. (RV41) stock withstand sector downturns2025 Trade Ideas & Expert Verified Stock Movement Alerts - Newser
How analysts revise price targets for Fennec Pharmaceuticals Inc. (RV41) stockJuly 2025 Breakouts & Safe Entry Point Identification - Newser
(FENC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Will Fennec Pharmaceuticals Inc. (RV41) stock benefit from Fed rate cutsDay Trade & Smart Allocation Stock Reports - Newser
Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan - MSN
Why Fennec Pharmaceuticals Inc. stock is popular among millennialsMarket Weekly Review & Daily Volume Surge Signals - Newser
(FRX) Technical Pivots with Risk Controls (FRX:CA) - news.stocktradersdaily.com
Is Fennec Pharmaceuticals Inc. stock resilient to inflationInflation Watch & Fast Entry Momentum Alerts - Newser
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Can Fennec Pharmaceuticals Inc. stock attract ESG capital inflows2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
Fennec Pharmaceuticals : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Stocks in play: Fennec Pharmaceuticals Inc. - The Globe and Mail
Fennec Pharmaceuticals Inc Announces Positive Results from PEDMARK® Trial in Japan - TradingView
Wedbush on Fennec Pharmaceuticals Latest Japan Trial Results - marketscreener.com
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Benzinga
Fennec Pharmaceuticals announces positive topline results - marketscreener.com
Fennec Pharmaceuticals Inc. Announces Positive Topline Results from Investigator-Initiated Clinical Study of Pedmark®? in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Reports Positive Top-line Results From Japan Trial - marketscreener.com
Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint - marketscreener.com
Fennec’s pediatric hearing protection drug shows positive results in Japan By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Brief: Announcing "Positive" Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss - The Manila Times
Is Fennec Pharmaceuticals Inc. (RV41) stock a buy before new product rolloutQuarterly Trade Report & Daily Stock Trend Reports - Newser
(FRX) Long Term Investment Analysis (FRX:CA) - news.stocktradersdaily.com
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33 - Defense World
(FRX) Technical Data (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
Fennec Pharmaceuticals Inc Azioni (FENC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):